Company Overview of Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The company’s principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. It also develops other central nervous systems active peptides, as second-generation medications for the treatment of depression, anxiety, and other psychiatric disorders. The company is headquartered in Syosset, New York.
6901 Jericho Turnpike
Syosset, NY 11791
Key Executives for Tetragenex Pharmaceuticals, Inc.
Chairman of the Board and Co-Chief Executive Officer
Vice Chairman, Co-Chief Executive Officer, Treasurer and Member of Compensation Committee
Chief Operating Officer and Director
Chief Scientific Officer, Senior Vice President of Drug Development & Regulatory Affairs and Director
Vice President of Operations and Secretary
Compensation as of Fiscal Year 2015.
Tetragenex Pharmaceuticals, Inc. Key Developments
SEC Revokes Registration Of Registered Securities Of Tetragenex Pharmaceuticals
Nov 14 13
An Administrative Law Judge issued an Initial Decision on Default as to Tetragenex Pharmaceuticals, Inc. in Skyview Holdings Corp., Admin. Proc. File No. 3-15515. The Initial Decision found that the company is the issuer of securities registered pursuant to Section 12(g) of the Securities Exchange Act of 1934 (Exchange Act), and that it has failed to comply with Section 13(a) of the Exchange Act and Exchange Act Rules 13a-1 and/or 13a-13 by failing to file required periodic reports with the Securities and Exchange Commission (SEC or The Commission). As a result, the Administrative Law Judge found it was necessary and appropriate for the protection of investors to revoke the registration of each class of the company’ registered securities.
SEC Orders Hearing On Registration Suspension Or Revocation Against Tetragenex Pharmaceuticals
Sep 23 13
On September 23, 2013, the Securities and Exchange Commission (SEC) instituted public administrative proceeding to determine whether to revoke or suspend for a period not exceeding twelve months the registrations of each class of the securities of Tetragenex Pharmaceuticals, Inc. for failure to make required periodic filings with the Commission. In this Order, the Division of Enforcement (Division) alleges that the company is delinquent in its required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the Administrative Law Judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and/or 13a-13 there under, are true. The Administrative Law Judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of the company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceeding.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries